Hims & Hers Jumps 12% As Bull Projects $10B-$19B Peptide Revenue by 2030
HIMS•Hims & Hers shares rose 12% to $30.17, their best two-month performance, after bullish forecasts for its peptide segment. A 4%-5% market share in a $250B-$380B global peptide market could yield $10B-$19B in annual revenue by 2030.
1. Stock’s Best Day in Two Months
Hims & Hers shares rallied over 12% to close at $30.17 Monday, marking their strongest single-day gain since early April as investors reacted to optimistic growth forecasts for the company’s peptide offerings.
2. Bull Forecasts Peptide Revenue
An investor projects the global peptide market will reach $250B-$380B in annual sales by 2030, estimating that a 4%-5% share could translate into $10B-$19B in peptide revenue for Hims & Hers.
3. Analyst Rating and Price Target
Canaccord reiterated a Buy rating and $32 price target on Hims & Hers, highlighting peptides as a potential long-term growth engine and implying roughly 6% upside from current levels.
4. Growth Drivers and Risks
Rising consumer interest and regulatory support are cited as tailwinds for Hims’ peptide push, though questions remain about branded versus compounded product margins and the company’s ultimate profitability in this segment.
